In the dynamic world of global medicines development, Medical Affairs is undergoing a transformation. Once seen primarily as a post-launch support function, it is now recognized as a strategic driver of value throughout the product lifecycle—influencing early development decisions, shaping evidence strategies, and aligning access pathways.
This evolution reflects a broader industry shift that experts from ZS Associates and IQVIA have documented across recent analyses—and it is precisely what the GMDP Academy’s Module 2: Medical Affairs and Health Economics prepares its students to lead.

The New Reality: Earlier Engagement, Bigger Impact

The ZS Medical Affairs Outlook 2025 highlights that medical affairs organizations are expanding beyond their traditional post-launch scope, becoming more proactive partners in early evidence planning, payer engagement, and health-economic value demonstration (ZS Associates, 2025).
The report identifies several trends reshaping the function:

  • Earlier integration into development programs — ensuring that clinical and real-world data meet payer and regulatory expectations.
  • Digital and non-personal engagement — using omnichannel tools to extend credible scientific communication well before commercialization.
  • A broadened stakeholder network — engaging not only clinicians, but also payers, patient advocates, regulators, and policymakers.

Similarly, IQVIA’s publication “Medical Affairs: Strategic Partner to Other Functions” observes that Medical Affairs can add value throughout development by helping align internal evidence strategies and external engagement, strengthening a product’s scientific foundation (IQVIA, 2023).
And in IQVIA’s Launch Excellence 2025 blog, analysts note that effective launches depend on early, integrated evidence generation and relationship-building, reinforcing Medical Affairs as a critical partner for pre-launch success (IQVIA, 2025).

Together, these insights confirm a clear trend: Medical Affairs is moving upstream—actively shaping evidence and value narratives before launch.

Aligning Science, Evidence, and Access

The move toward earlier engagement reflects a fundamental industry reality: innovation must now demonstrate not only clinical effectiveness but also economic and societal value.
As ZS Associates (2025) notes, the organizations leading in Medical Affairs maturity are embedding Health Economics and Outcomes Research (HEOR) expertise into early evidence strategies, ensuring that payer expectations and real-world data requirements are integrated into trial and communication planning.

This shift aligns precisely with the GMDP Academy’s Module 2, which combines the disciplines of Medical Affairs and Health Economics to equip professionals with the skills to evaluate cost-effectiveness, interpret health-technology assessments (HTAs), and communicate value transparently across stakeholders.

Students learn to connect clinical data, patient outcomes, and economic sustainability—preparing them to support access strategies that meet the needs of regulators, payers, and patients alike.

Medical Affairs as the Ethical Bridge

Medical Affairs professionals now occupy a unique position in the pharmaceutical ecosystem: they are guardians of scientific integrity and architects of access strategy.
The GMDP Academy emphasizes that this dual responsibility requires both technical expertise and ethical leadership. Rather than acting as a gatekeeper, Medical Affairs serves as a bridge—linking scientific truth with public trust.

Student perspectives from recent CMD cohorts reflect this transformation.
Katrine Møller, Senior Medical Affairs Scientist, Pfizer (Denmark), shared that maintaining clear boundaries between education and promotion “helps healthcare professionals make unbiased decisions and ensures that our consumers receive accurate and informative messaging about prescription drugs”.
Likewise, Ishita Sengupta, Pfizer (India), highlighted that today’s framework is shifting “from an inward, product-focused view to an outward, patient- and stakeholder-centric approach—creating awareness, acceptability, affordability, and accessibility”.

Their reflections embody the evolving identity of Medical Affairs—where ethics, communication, and evidence converge to deliver tangible health value.

Why It Matters Now

As the industry faces increasing expectations for transparency, evidence, and affordability, the ability to align scientific data with ethical and economic perspectives has become a core competency.
The IQVIA Launch Excellence Report 2025 reinforces that launch success depends on early scientific engagement, cross-functional planning, and value demonstration—areas now firmly within the Medical Affairs remit.

This transformation mirrors what students experience in the GMDP Academy’s Module 2: a curriculum that moves beyond knowledge to application, training professionals to think like strategic partners and communicate as ethical leaders.

Preparing the Next Generation of Strategic Medical Leaders

Medical Affairs is no longer the endpoint of drug development—it is a strategic compass, guiding discovery, development, and access decisions.
Through Module 2: Medical Affairs and Health Economics, the GMDP Academy equips students to lead in this new paradigm—where success depends on their ability to integrate scientific integrity, economic insight, and ethical stewardship from the earliest stages of development.

References

  • IQVIA. (2023). Medical Affairs: Strategic Partner to Other Functions. Retrieved from https://www.iqvia.com
  • IQVIA. (2025, February). Launch Excellence: Five Foundational Success Factors. Retrieved from https://www.iqvia.com
  • ZS Associates. (2025). Medical Affairs Outlook Report 2025. Retrieved from https://www.zs.com

ZS Associates. (2024). The Future of Medical Affairs: Scaling Knowledge Dissemination with Transformative Approaches. Retrieved from https://www.zs.com

Disclaimers

  • The material in these reviews is from various public open access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred